The Symphony of Survival: Sacubitril/Valsartan’s Heartfelt Impact on Mortality in Heart Failure: A Systemic Review

Abstract

Heart failure (HF) is a prevalent and debilitating
condition affecting millions worldwide. Over the years,
numerous therapeutic strategies have been employed
to manage HF, improving patients' quality of life, and
reducing morbidity and mortality rates.
Sacubitril/valsartan, a novel combination drug, has
emerged as a promising therapeutic option in the
management of HF with reduced ejection fraction
(HFrEF This abstract provides a comprehensive review
of the use of sacubitril/valsartan in treating HF patients.
It delves into the mechanism of action of both
components, examining how sacubitril, a neprilysin
inhibitor, and valsartan, an angiotensin receptor blocker,
work synergistically to address the complex
pathophysiology of HFrEF. The unique combination of
these agents has been shown to improve cardiac
function, reduce ventricular remodeling, and mitigate
neurohormonal activation, leading to better outcomes
in HF patients. Several clinical trials and real-world
studies have demonstrated the efficacy and safety of
sacubitril/valsartan in HF management. These studies
have highlighted the drug's ability to reduce HF-related
hospitalizations and improve patients' functional status
and exercise tolerance. Moreover, the combination
therapy has shown a favorable risk-benefit profile,
making it a valuable option for HF patients intolerant to
angiotensin-converting enzyme (ACE) inhibitors.